Beaver Run Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2018
Here are the related meetings in 2020:
Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities (J4)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Cancer Epigenetics: New Mechanisms, New Therapies (B4)
Organizer(s) François Fuks and Anne Brunet
February 10—14, 2018
Beaver Run Resort • Breckenridge, CO USA
Discounted Abstract Deadline: Oct 10, 2017
Abstract Deadline: Nov 8, 2017
Scholarship Deadline: Oct 10, 2017
Discounted Registration Deadline: Dec 12, 2017
Sponsored by Cancer Research UK, Cell Research, Incyte Corporation, Merck & Co., Inc., Novartis Institutes for BioMedical Research, Pfizer Inc. and Roche
Summary of Meeting:
The field of epigenetics has recently emerged as an essential component of oncology research, with altered epigenetic modifications considered to be critical hallmarks of cancers. Unlike mutations, epigenetic aberrations are reversible and as a result, epigenetic therapies hold great promise as anti-cancer agents. For these novel therapies to succeed, a key challenge is to fully understand the nature and the mechanisms that lead to epigenetic changes in cancer. Another essential challenge is to make sense of the avalanche of data flowing from increasingly powerful "omics-based" technologies. Despite these challenges, never has the potential for scientific and clinical breakthroughs in this field been greater. Bringing together both the academic and the pharmaceutical communities, this Keystone Symposia conference will focus on: 1) The newest findings concerning the mechanisms by which epigenetic pathways are established and maintained in normal and stem cells, and how these go awry during aging and cancer, with a special emphasis on histone modifications, chromatin remodeling and the unexpected increased number of DNA modifications ((hydroxy)methylcytosine and methyladenine); 2) The growing roles of noncoding RNAs in cancer and the emergence of the new and exciting realm of RNA epigenetics; 3) Use of new omics technologies to interrogate altered epigenetic landscapes in tumors and assess their clinical implications; and 4) Novel and promising therapeutic drugs aimed at reversing specific epigenetic alterations. Ultimately, the meeting will provide great opportunities for senior and junior scientists to meet the leaders in the field from both academia and industry, hence forging exciting interdisciplinary interactions and creating potential new collaborations in the burgeoning area of cancer epigenetics.
View Scholarships/Awards
The field of epigenetics has recently emerged as an essential component of oncology research, with altered epigenetic modifications considered to be critical hallmarks of cancers. Unlike mutations, epigenetic aberrations are reversible and as a result, epigenetic therapies hold great promise as anti-cancer agents. For these novel therapies to succeed, a key challenge is to fully understand the nature and the mechanisms that lead to epigenetic changes in cancer. Another essential challenge is to make sense of the avalanche of data flowing from increasingly powerful "omics-based" technologies. Despite these challenges, never has the potential for scientific and clinical breakthroughs in this field been greater. Bringing together both the academic and the pharmaceutical communities, this Keystone Symposia conference will focus on: 1) The newest findings concerning the mechanisms by which epigenetic pathways are established and maintained in normal and stem cells, and how these go awry during aging and cancer, with a special emphasis on histone modifications, chromatin remodeling and the unexpected increased number of DNA modifications ((hydroxy)methylcytosine and methyladenine); 2) The growing roles of noncoding RNAs in cancer and the emergence of the new and exciting realm of RNA epigenetics; 3) Use of new omics technologies to interrogate altered epigenetic landscapes in tumors and assess their clinical implications; and 4) Novel and promising therapeutic drugs aimed at reversing specific epigenetic alterations. Ultimately, the meeting will provide great opportunities for senior and junior scientists to meet the leaders in the field from both academia and industry, hence forging exciting interdisciplinary interactions and creating potential new collaborations in the burgeoning area of cancer epigenetics.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Saturday, February 10 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, February 14 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Thursday, February 15 in order to fully experience the meeting.
SATURDAY, FEBRUARY 10
SUNDAY, FEBRUARY 11
MONDAY, FEBRUARY 12
TUESDAY, FEBRUARY 13
WEDNESDAY, FEBRUARY 14
THURSDAY, FEBRUARY 15
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Saturday, February 10 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, February 14 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Thursday, February 15 in order to fully experience the meeting.
SATURDAY, FEBRUARY 10
08:00—09:00
Welcome and Keynote Address
*
François Fuks,
Université Libre de Bruxelles, Belgium
*
Anne Brunet,
Stanford University, USA
Tony Kouzarides,
University of Cambridge, UK
Modifications of RNA: Their Function and Role in Cancer
Modifications of RNA: Their Function and Role in Cancer
09:00—11:30
Epigenetic Mechanisms and Cancer
*
Anne Brunet,
Stanford University, USA
Geneviève Almouzni,
Centre National de la Recherche Scientifique, France
Chromatin Determinants of Centromeric Identity and their Deregulation in Cancer
Chromatin Determinants of Centromeric Identity and their Deregulation in Cancer
Adrian P. Bracken,
Trinity College Dublin, Ireland
Short Talk: A New Family of Vertebrate-Specific Polycombs Balance PRC2 Subtype Activities
Short Talk: A New Family of Vertebrate-Specific Polycombs Balance PRC2 Subtype Activities
Coffee Break
François Fuks,
Université Libre de Bruxelles, Belgium
Transcriptome-Wide Distribution and Function of RNA Modifications in Cancer
Transcriptome-Wide Distribution and Function of RNA Modifications in Cancer
Panagiotis Ntziachristos,
Northwestern University, USA
Short Talk: Active Deubiquitination as a Molecular Rheostat Controlling Resistance to Therapy in Acute Leukemia
Short Talk: Active Deubiquitination as a Molecular Rheostat Controlling Resistance to Therapy in Acute Leukemia
17:00—19:30
Chromatin Dysregulations in Cancer
*
Johnathan R. Whetstine,
Fox Chase Cancer Center, USA
Luciano Di Croce,
CRG - Center for Genomic Regulation, Spain
Role of Polycomb and MLL Complexes in Nuclear Architecture and Gene Regulation
Role of Polycomb and MLL Complexes in Nuclear Architecture and Gene Regulation
Cigall Kadoch,
Dana-Farber Cancer Institute, Harvard Medical School, USA
BAF Complex Structure and Function in Human Cancer
BAF Complex Structure and Function in Human Cancer
Tom Owen-Hughes,
University of Dundee, Scotland
Short Talk: Variation in the Protein Composition of SWI/SNF Chromatin Remodeling Complexes in Clear Cell Renal Carcinoma
Short Talk: Variation in the Protein Composition of SWI/SNF Chromatin Remodeling Complexes in Clear Cell Renal Carcinoma
Ozgur Oksuz,
New York University School of Medicine, USA
Capturing the Onset of Polycomb Domain Formation
Capturing the Onset of Polycomb Domain Formation
19:30—20:30
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Emergence of Epitranscriptomics
*
Cigall Kadoch,
Dana-Farber Cancer Institute, Harvard Medical School, USA
Lu Wang,
Northwestern University, USA
Resetting the Epigenetic Balance of Polycomb/COMPASS Function for Cancer Therapy
Resetting the Epigenetic Balance of Polycomb/COMPASS Function for Cancer Therapy
Chuan He,
University of Chicago, USA
Aberrant RNA Methylation in Human Cancers
Aberrant RNA Methylation in Human Cancers
Ulrike Litzenburger,
Stanford University, USA
Short Talk: Direct Linkage of Cancer Cell Epigenomic State with Phenotype using Multi-Index Single-Cell ATAC-Seq
Short Talk: Direct Linkage of Cancer Cell Epigenomic State with Phenotype using Multi-Index Single-Cell ATAC-Seq
Coffee Break
Gideon Rechavi,
Tel Aviv University, Israel
Cancer Epitranscriptomics
Cancer Epitranscriptomics
Brian J. Abraham,
St. Jude Children's Research Hospital, USA
Short Talk: Three-Dimensional Gene Regulatory Landscapes in Normal and Cancer Cells
Short Talk: Three-Dimensional Gene Regulatory Landscapes in Normal and Cancer Cells
Gerald R. Crabtree,
Stanford University, USA
Pathogenic Mechanisms in the Opposition of BAF(mSWI/SNF) and Polycomb in Human Cancer
Pathogenic Mechanisms in the Opposition of BAF(mSWI/SNF) and Polycomb in Human Cancer
17:00—19:00
Chromatin Assembly, Stem Cells and Aging
*
Karen Adelman,
Harvard Medical School, USA
Robert E. Kingston,
Massachusetts General Hospital, USA
Nucleosome Compaction and Polycomb-Group Repressive Function during Development
Nucleosome Compaction and Polycomb-Group Repressive Function during Development
Johnathan R. Whetstine,
Fox Chase Cancer Center, USA
Epigenetics as a Gatekeeper to DNA Amplification
Epigenetics as a Gatekeeper to DNA Amplification
Ernesto Guccione,
Institute of Molecular and Cell Biology, Singapore
Short Talk: Investigating the Function of PRDM Proteins in Stem Cells and Cancer
Short Talk: Investigating the Function of PRDM Proteins in Stem Cells and Cancer
Anne Brunet,
Stanford University, USA
Epigenetic and Metabolic Regulation of Aging and Rejuvenation
Epigenetic and Metabolic Regulation of Aging and Rejuvenation
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
DNA (de)Methylation Dynamics and Cancer
*
Kornelia Polyak,
Dana-Farber Cancer Institute, Harvard Medical School, USA
Stephen B. Baylin,
Johns Hopkins University School of Medicine, USA
DNA Methylation in Stem Cell and Cancer
DNA Methylation in Stem Cell and Cancer
Luisa Cimmino,
New York University, USA
Short Talk: Restoration of TET Function as a Therapeutic Strategy in Leukemia
Short Talk: Restoration of TET Function as a Therapeutic Strategy in Leukemia
Coffee Break
Salvador Aznar Benitah,
ICREA and Institute for Research in Biomedicine, Spain
Epigenetic Mechanisms in Adult Stem Cell Function, and their Impact over Mutational Burden of Cancer Stem Cells
Epigenetic Mechanisms in Adult Stem Cell Function, and their Impact over Mutational Burden of Cancer Stem Cells
Timothy C. Hallstrom,
University of Minnesota, USA
Short Talk: UHRF2 Control of 5hmC Homeostasis and Differentiation in Retinal Progenitor Cells
Short Talk: UHRF2 Control of 5hmC Homeostasis and Differentiation in Retinal Progenitor Cells
Karen Adelman,
Harvard Medical School, USA
Probing Transcription Regulation at Enhancers
Probing Transcription Regulation at Enhancers
17:00—19:00
Connecting Noncoding RNAs and Cancer
*
Salvador Aznar Benitah,
ICREA and Institute for Research in Biomedicine, Spain
John L. Rinn,
University of Colorado Boulder, USA
A Conserved TAD Boundary Organization at the Firre lncRNA Locus Is Resistant to Loss of Numerous CTCF Binding Sites
A Conserved TAD Boundary Organization at the Firre lncRNA Locus Is Resistant to Loss of Numerous CTCF Binding Sites
Yotam Drier,
MGH and Harvard Medical School, USA
Short Talk: Epigenetic Inhibition of CTCF Insulation in Cancer
Short Talk: Epigenetic Inhibition of CTCF Insulation in Cancer
Robert A. Martienssen,
Cold Spring Harbor Laboratory, USA
Replication-Coupled Silencing and Spreading with RNAi
Replication-Coupled Silencing and Spreading with RNAi
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Novel Therapeutic Discoveries in Epigenetics I
*
John L. Rinn,
University of Colorado Boulder, USA
Mark A. Dawson,
Peter MacCallum Cancer Centre, Australia
Molecular Mechanisms Governing Sensitivity and Resistance to Epigenetic Therapies
Molecular Mechanisms Governing Sensitivity and Resistance to Epigenetic Therapies
Danette L. Daniels,
Promega Corporation, USA
Short Talk: Understanding the Functional Pathway of BET Family Degradation Compounds
Short Talk: Understanding the Functional Pathway of BET Family Degradation Compounds
Kornelia Polyak,
Dana-Farber Cancer Institute, Harvard Medical School, USA
KDM5B Links Cellular Transcriptome Heterogeneity to Therapy Resistance
KDM5B Links Cellular Transcriptome Heterogeneity to Therapy Resistance
Coffee Break
Robert MacLeod,
Ionis Pharmaceuticals, Inc., USA
Next Generation Antisense Oligonucleotides as Therapeutic Inhibitors of LncRNAs for the Treatment of Cancer
Next Generation Antisense Oligonucleotides as Therapeutic Inhibitors of LncRNAs for the Treatment of Cancer
Allison E. Drew,
Epizyme, USA
Short Talk: Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma
Short Talk: Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma
Ronan C. O'Hagan,
Merck Research Laboratories, USA
Epigenetics and Immune Modulation in Cancer
Epigenetics and Immune Modulation in Cancer
14:00—16:30
Workshop: Epigenetic Pathways and Cancer
*
Tom Owen-Hughes,
University of Dundee, Scotland
Giovanni Ciriello,
University of Lausanne, Switzerland
The Landscape of Aberrant DNA Methylation across Human Cancers
The Landscape of Aberrant DNA Methylation across Human Cancers
Robert M. Witwicki,
Dana-Farber Cancer Institute, USA
Novel Epigenetic Dependencies of Human Cancers
Novel Epigenetic Dependencies of Human Cancers
Noa Furth,
Weizmann Institute of Science, Israel
Rewiring of Tumor Suppressors Networks: LATS Kinases and p53
Rewiring of Tumor Suppressors Networks: LATS Kinases and p53
Sandra Schick,
CeMM GmbH, Austria
Loss of Specific Mammalian BAF Subunits Causes Global Changes in Chromatin Accessibility
Loss of Specific Mammalian BAF Subunits Causes Global Changes in Chromatin Accessibility
Molly Kingsley,
University of Colorado, USA
The Role of H3K79 Methylation in IDH Mutant AML
The Role of H3K79 Methylation in IDH Mutant AML
Elisa Oricchio,
École Polytechnique Fédérale de Lausanne, Switzerland
Oncogenic Mutation of EZH2 Inactivates Tumor- Suppressive TADs to Promote Lymphomagenesis
Oncogenic Mutation of EZH2 Inactivates Tumor- Suppressive TADs to Promote Lymphomagenesis
David I. Remillard,
Harvard University, USA
Targeted Degradation of BRD9 as a Therapeutic Strategy in BAF-Dependent Cancers
Targeted Degradation of BRD9 as a Therapeutic Strategy in BAF-Dependent Cancers
Lingyan Jin,
Genentech, Inc., USA
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
17:00—18:45
Novel Therapeutic Discoveries in Epigenetics II
*
Mark A. Dawson,
Peter MacCallum Cancer Centre, Australia
Myriem Boufraqech,
NCI, National Institutes of Health, USA
Targeting the Epigenome in Endocrine Cancers
Targeting the Epigenome in Endocrine Cancers
Rab K. Prinjha,
GlaxoSmithKline, UK
Epigenetic Targets for the Treatment of Human Diseases
Epigenetic Targets for the Treatment of Human Diseases
James E. Bradner,
Novartis Institutes for BioMedical Research, USA
Targeted Degradation of Chromatin-Associated Transcription Factors
Targeted Degradation of Chromatin-Associated Transcription Factors
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
